ProRetina Therapeutics Overview
- Founded
- 2007
- Status
- Out of Business
- Employees
- 10
- Latest Deal Type
- Liquidation
ProRetina Therapeutics General Information
Description
Developer of therapeutics and drugs designed to be used for the treatment of retinal dystrophies and degenerations. The company's products contain active ingredient, a neuroprotective agent which is highly effective in treating retinitis pigmentosa, a degenerative disease of genetic origins, enabling patients and healthcare institutions to avail cure to stop blindness in the adult age.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
- Plaza CEIN, 5
- 31110 Noáin
- Spain
ProRetina Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Bankruptcy: Liquidation | 30-Sep-2018 | 00.000 | Completed | Bankruptcy: Liquidation | ||
| 5. Early Stage VC (Series A) | 15-Aug-2013 | 00.000 | Completed | Generating Revenue | ||
| 4. Grant | 00.000 | Completed | Startup | |||
| 3. Seed Round | 15-Sep-2012 | 00.000 | 00.000 | Completed | Startup | |
| 2. Early Stage VC | 24-Sep-2010 | $490K | $3.88M | Completed | Startup | |
| 1. Early Stage VC | 02-Apr-2010 | $3.39M | $3.39M | Completed | Startup |
ProRetina Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial